Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Nov 3, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Phase III Trial Finds Equivalent OS Rates Between APBI Brachytherapy and Whole Breast Irradiation Therapy 

 

A prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation with interstitial multicatheter brachytherapy to whole breast irradiation showed that APBI brachytherapy lead to equivalent overall survival and local and regional cancer control rates, as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers.

The primary objective of the trial was to assess the role of APBI brachytherapy alone compared to whole breast irradiation with boost in a defined group of patients with invasive (stage I-IIA) breast cancer or ductal carcinoma in situ (stage 0) who underwent breast-conserving surgery.

Researchers evaluated a total of 1,184 patients aged 40 years and above who were randomized to a standardized treatment arm involving whole breast irradiation (n=551) or the APBI treatment arm (n=633).



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter